» Articles » PMID: 12663750

Activation of the Cannabinoid Receptor Type 1 Decreases Glutamatergic and GABAergic Synaptic Transmission in the Lateral Amygdala of the Mouse

Overview
Journal Learn Mem
Specialty Neurology
Date 2003 Mar 29
PMID 12663750
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

The endogenous cannabinoid system has been shown recently to play a crucial role in the extinction of aversive memories. As the amygdala is presumably involved in this process, we investigated the effects of the cannabinoid receptor agonist WIN 55,212-2 (WIN-2) on synaptic transmission in the lateral amygdala (LA) of wild-type and cannabinoid receptor type 1 (CB1)-deficient mice. Extracellular field potential recordings and patch-clamp experiments were performed in an in vitro slice preparation. We found that WIN-2 reduces basal synaptic transmission and pharmacologically isolated AMPA receptor- and GABA(A) receptor-mediated postsynaptic currents in wild-type, but not in CB1-deficient mice. These results indicate that, in the LA, cannabinoids modulate both excitatory and inhibitory synaptic transmission via CB1. WIN-2-induced changes of paired-pulse ratio and of spontaneous and miniature postsynaptic currents suggest a presynaptic site of action. Inhibition of G(i/o) proteins and blockade of voltage-dependent and G protein-gated inwardly rectifying K(+) channels inhibited WIN-2 action on basal synaptic transmission. In contrast, modulation of the adenylyl cyclase-protein kinase A pathway, and blockade of presynaptic N- and P/Q- or of postsynaptic L- and R/T-type voltage-gated Ca(2+) channels did not affect WIN-2 effects. Our results indicate that the mechanisms underlying cannabinoid action in the LA partly resemble those observed in the nucleus accumbens and differ from those described for the hippocampus.

Citing Articles

Cholecystokinin-expressing interneurons mediated inhibitory transmission and plasticity in basolateral amygdala modulate stress-induced anxiety-like behaviors in mice.

Fang W, Chen X, He J Neurobiol Stress. 2024; 33:100680.

PMID: 39502835 PMC: 11536064. DOI: 10.1016/j.ynstr.2024.100680.


Effects of Cannabis on Glutamatergic Neurotransmission: The Interplay between Cannabinoids and Glutamate.

Chowdhury K, Holden M, Wiley M, Suppiramaniam V, Reed M Cells. 2024; 13(13.

PMID: 38994982 PMC: 11240741. DOI: 10.3390/cells13131130.


Toluene alters the intrinsic excitability and excitatory synaptic transmission of basolateral amygdala neurons.

Braunscheidel K, Okas M, Woodward J Front Neurosci. 2024; 18:1366216.

PMID: 38595974 PMC: 11002899. DOI: 10.3389/fnins.2024.1366216.


Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.

Scheyer A, Yasmin F, Naskar S, Patel S Neuropsychopharmacology. 2022; 48(1):37-53.

PMID: 36100658 PMC: 9700791. DOI: 10.1038/s41386-022-01438-7.


Effects of Δ9-Tetrahydrocannibinol (THC) on Obesity at Different Stages of Life: A Literature Review.

Fearby N, Penman S, Thanos P Int J Environ Res Public Health. 2022; 19(6).

PMID: 35328862 PMC: 8951828. DOI: 10.3390/ijerph19063174.


References
1.
Porter A, Felder C . The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther. 2001; 90(1):45-60. DOI: 10.1016/s0163-7258(01)00130-9. View

2.
Deadwyler S, Hampson R, Mu J, Whyte A, Childers S . Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther. 1995; 273(2):734-43. View

3.
Hoffman A, Lupica C . Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. J Neurophysiol. 2001; 85(1):72-83. DOI: 10.1152/jn.2001.85.1.72. View

4.
Wilson R, Nicoll R . Endocannabinoid signaling in the brain. Science. 2002; 296(5568):678-82. DOI: 10.1126/science.1063545. View

5.
Bordey A, Sontheimer H . Differential inhibition of glial K(+) currents by 4-AP. J Neurophysiol. 1999; 82(6):3476-87. DOI: 10.1152/jn.1999.82.6.3476. View